Vitality Watch

Dossier clinicaltrials trial early 15-jun-2026
Small or early-phase human trial or pilot study

CBD for Individuals at Risk for Alzheimer’s Disease

Key claim: A double-blind randomized controlled trial is testing whether cannabidiol (CBD) improves validated Alzheimer’s progression biomarkers and behavioral, neurocognitive, and clinical measures in individuals at risk for AD.

Abstract

This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer’s disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.

Why this matters

CBD is widely consumed as a wellness supplement, but rigorous human outcome data in aging-relevant contexts is thin; a double-blind RCT anchored to validated Alzheimer’s biomarkers in at-risk individuals would move CBD from the anecdotal/mechanism tier toward direct clinical evidence in neurodegeneration. Until the trial reports, the finding is a design signal only — the gap between popular CBD use and confirmed disease-modifying effect remains the story.

Source

Link

Briefing card

CBD for Individuals at Risk for Alzheimer's Disease
Stage: trial early · clinicaltrials · 15-jun-2026

A double-blind randomized controlled trial is testing whether cannabidiol (CBD) improves validated Alzheimer’s progression biomarkers and behavioral, neurocognitive, and clinical measures in individuals at risk for AD.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT05822362

build build 880 · 2bcef25 · 2026-11-18